iRadimed Corporation (NASDAQ:IRMD) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• iRadimed has a “Moderate Buy” consensus rating from five analysts, with two buys, one strong buy and two holds. The average 12-month price target is $120, compared with a recent share price of $86.59.
• The company slightly exceeded quarterly expectations, reporting EPS of $0.46 versus the $0.44 consensus and revenue of $20.47 million versus $20.35 million expected. Management provided fiscal 2026 EPS guidance of $2.09–$2.24.
• iRadimed paid a quarterly dividend of $0.20 per share, equivalent to an annualized $0.80 dividend and a 0.9% yield. Institutional investors own a substantial 92.34% of the company, with several major funds recently building positions.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) has earned an average rating of "Moderate Buy" from the five analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $120.00.

Several research firms recently issued reports on IRMD. Weiss Ratings lowered shares of iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, August 3rd. Wall Street Zen downgraded shares of iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th.

iRadimed Price Performance

Shares of iRadimed stock opened at $86.59 on Friday. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 48.37 and a beta of 0.89. The stock has a 50-day simple moving average of $92.42 and a 200-day simple moving average of $93.72. iRadimed has a 52-week low of $67.84 and a 52-week high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The firm had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, equities research analysts predict that iRadimed will post 1.98 earnings per share for the current year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, August 14th. iRadimed's dividend payout ratio is 44.69%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in iRadimed in the 2nd quarter worth approximately $92,485,000. California State Teachers Retirement System grew its holdings in iRadimed by 12,018.2% during the second quarter. California State Teachers Retirement System now owns 954,549 shares of the medical equipment provider's stock valued at $91,217,000 after purchasing an additional 946,672 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider's stock valued at $24,893,000 after purchasing an additional 205,783 shares during the period. Ranger Investment Management L.P. bought a new position in shares of iRadimed in the second quarter valued at approximately $9,398,000. Finally, Bank of New York Mellon Corp bought a new position in shares of iRadimed in the second quarter valued at approximately $7,252,000. Institutional investors and hedge funds own 92.34% of the company's stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source